Patient characteristics
| Characteristics | BIBF 1120 | |
|---|---|---|
| Once daily | Twice daily | |
| No. of patients | 25 | 36 |
| Gender | ||
| Male (n) | 15 | 31 |
| Female (n) | 10 | 5 |
| Age | 59 (41-74) | 63 (34-83) |
| Median (range) | ||
| ECOG performance status at baseline | ||
| 0 | 7 | 9 |
| 1 | 17 | 26 |
| 2 | 1 | 1 |
| Prior therapy | ||
| Surgery | 23 | 33 |
| Chemotherapy | 24 | 29 |
| Radiotherapy | 9 | 15 |
| Immunotherapy* | 5 | 8 |
| Hormonal therapy | 1 | 4 |
| Tumor type | ||
| Colorectal | 14 | 16 |
| Kidney, ureter | 1 | 9 |
| Pleura | 3 | 2 |
| Prostate | 0 | 3 |
| Breast | 2 | 0 |
| Sarcoma, soft tissue | 1 | 1 |
| Head and neck | 0 | 2 |
| Lung | 0 | 2 |
| Pancreas | 1 | 0 |
| Liver, biliary tree | 2 | 0 |
| Cervix, vagina and vulva | 1 | 0 |
| Thyroid | 0 | 1 |
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
↵*Immunotherapy comprised, e.g., IFN, interleukin, levamisole.